메뉴 건너뛰기




Volumn 165, Issue 2, 2012, Pages 254-258

Erratum: Expression of concern to “Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study” [EJOG 165(2) (2012) 254–258, (S0301211512003661), (10.1016/j.ejogrb.2012.08.008)];Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study

Author keywords

Cabergoline; Dopamine agonist; OHSS; RCT

Indexed keywords

CABERGOLINE; CHORIONIC GONADOTROPIN;

EID: 84870296389     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2024.06.009     Document Type: Erratum
Times cited : (32)

References (32)
  • 2
    • 68149161009 scopus 로고    scopus 로고
    • Symposium: Update on prediction and management of OHSS. Prevention of OHSS
    • M. Aboulghar Symposium: update on prediction and management of OHSS. Prevention of OHSS Reproductive Biomedicine Online 19 2009 33 42
    • (2009) Reproductive Biomedicine Online , vol.19 , pp. 33-42
    • Aboulghar, M.1
  • 3
    • 64949160399 scopus 로고    scopus 로고
    • How to avoid ovarian hyperstimulation syndrome: A new indication for dopamine agonists
    • J.A. Garcia-Velasco How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists Reproductive Biomedicine Online 18 Suppl. 2 2009 71 75
    • (2009) Reproductive Biomedicine Online , vol.18 , Issue.SUPPL. 2 , pp. 71-75
    • Garcia-Velasco, J.A.1
  • 5
    • 77956378252 scopus 로고    scopus 로고
    • Ovarian hyperstimulation syndrome: Current views on pathophysiology, risk factors, prevention, and management
    • M.M. Alper, L.P. Smith, and E.S. Sills Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management Journal of Experimental & Clinical Assisted Reproduction 6 2009 3
    • (2009) Journal of Experimental & Clinical Assisted Reproduction , vol.6 , pp. 3
    • Alper, M.M.1    Smith, L.P.2    Sills, E.S.3
  • 7
    • 32944477548 scopus 로고    scopus 로고
    • Coasting for the prevention of ovarian hyperstimulation syndrome: Much ado about nothing?
    • J.A. García-Velasco, V. Isaza, G. Quea, and A. Pellicer Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertility and Sterility 85 2006 547 554
    • (2006) Fertility and Sterility , vol.85 , pp. 547-554
    • García-Velasco, J.A.1    Isaza, V.2    Quea, G.3    Pellicer, A.4
  • 9
    • 79952257347 scopus 로고    scopus 로고
    • Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles
    • M.A. Youssef, F. Van der Veen, and H.G. Al-Inany Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles Cochrane Database of Systematic Reviews 1 2011 CD008046
    • (2011) Cochrane Database of Systematic Reviews , vol.1 , pp. 008046
    • Youssef, M.A.1    Van Der Veen, F.2    Al-Inany, H.G.3
  • 10
    • 34547439801 scopus 로고    scopus 로고
    • IVF, IVM, natural cycle IVF, minimal stimulation
    • R.G. Edwards IVF, IVM, natural cycle IVF, minimal stimulation Reproductive Biomedicine Online 15 2007 106 119
    • (2007) Reproductive Biomedicine Online , vol.15 , pp. 106-119
    • Edwards, R.G.1
  • 13
    • 33751195510 scopus 로고    scopus 로고
    • Elective cryopreservation of embryos at the pronucleate stage in women at risk of ovarian hyperstimulation syndrome may affect the overall pregnancy rate
    • S. Vyjayanthi, T. Tang, A. Fattah, M. Deivanayagam, N. Bardis, and A.H. Balen Elective cryopreservation of embryos at the pronucleate stage in women at risk of ovarian hyperstimulation syndrome may affect the overall pregnancy rate Fertility and Sterility 86 2006 1773 1775
    • (2006) Fertility and Sterility , vol.86 , pp. 1773-1775
    • Vyjayanthi, S.1    Tang, T.2    Fattah, A.3    Deivanayagam, M.4    Bardis, N.5    Balen, A.H.6
  • 15
    • 0030824609 scopus 로고    scopus 로고
    • The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome
    • B. Rizk, M. Aboulghar, J. Smitz, and R. Ron-El The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome Human Reproduction Update 3 1997 255 266
    • (1997) Human Reproduction Update , vol.3 , pp. 255-266
    • Rizk, B.1    Aboulghar, M.2    Smitz, J.3    Ron-El, R.4
  • 16
    • 69049117170 scopus 로고    scopus 로고
    • High dose cabergoline in management of ovarian hyperstimulation syndrome
    • B. Ata, A. Seyhan, S. Orhaner, and B. Urman High dose cabergoline in management of ovarian hyperstimulation syndrome Fertility and Sterility 92 2009 1168 1174
    • (2009) Fertility and Sterility , vol.92 , pp. 1168-1174
    • Ata, B.1    Seyhan, A.2    Orhaner, S.3    Urman, B.4
  • 17
    • 45549084382 scopus 로고    scopus 로고
    • Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome
    • S.R. Soares, R. Gómez, C. Simón, J.A. García- Velasco, and A. Pellicer Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome Human Reproduction Update 14 2008 321 333
    • (2008) Human Reproduction Update , vol.14 , pp. 321-333
    • Soares, S.R.1    Gómez, R.2    Simón, C.3    García-Velasco, J.A.4    Pellicer, A.5
  • 18
    • 77949943219 scopus 로고    scopus 로고
    • The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: A randomized, double-blind, placebo-controlled trial
    • C. Busso, M. Fernández-Sánchez, and J.A. García-Velasco The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial Human Reproduction 25 2010 995 1004
    • (2010) Human Reproduction , vol.25 , pp. 995-1004
    • Busso, C.1    Fernández-Sánchez, M.2    García-Velasco, J.A.3
  • 19
    • 69049086527 scopus 로고    scopus 로고
    • Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: A case series
    • N.L. Rollene, M.H. Amols, S.B. Hudson, and C.C. Coddington Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Fertility and Sterility 92 2009 1169 1177
    • (2009) Fertility and Sterility , vol.92 , pp. 1169-1177
    • Rollene, N.L.1    Amols, M.H.2    Hudson, S.B.3    Coddington, C.C.4
  • 20
    • 33751247033 scopus 로고    scopus 로고
    • Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model
    • R. Gomez, M. Gonzalez-Izquierdo, and R.C. Zimmermann Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model Endocrinology 147 2006 5400 5411
    • (2006) Endocrinology , vol.147 , pp. 5400-5411
    • Gomez, R.1    Gonzalez-Izquierdo, M.2    Zimmermann, R.C.3
  • 21
    • 34547823052 scopus 로고    scopus 로고
    • Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction
    • C. Alvarez, L. Martí-Bonmatí, and E. Novella-Maestre Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction Journal of Clinical Endocrinology and Metabolism 92 2007 2931 2937
    • (2007) Journal of Clinical Endocrinology and Metabolism , vol.92 , pp. 2931-2937
    • Alvarez, C.1    Martí-Bonmatí, L.2    Novella-Maestre, E.3
  • 24
    • 58149103364 scopus 로고    scopus 로고
    • Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study
    • C. Carizza, V. Abdelmassih, and S. Abdelmassih Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study Reproductive Biomedicine Online 17 2008 751 755
    • (2008) Reproductive Biomedicine Online , vol.17 , pp. 751-755
    • Carizza, C.1    Abdelmassih, V.2    Abdelmassih, S.3
  • 25
    • 40449100155 scopus 로고    scopus 로고
    • Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: A pilot study
    • C. Alvarez, I. Alonso-Muriel, and G. García Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study Human Reproduction 22 2007 3210 3214
    • (2007) Human Reproduction , vol.22 , pp. 3210-3214
    • Alvarez, C.1    Alonso-Muriel, I.2    García, G.3
  • 26
    • 85197349062 scopus 로고    scopus 로고
    • Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone
    • Amsterdam, the Netherlands, 28 June-1 July
    • Salah Edeen AMR, Alhelou YM. Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Abstracts of the 25th annual meeting of ESHRE, Amsterdam, the Netherlands, 28 June-1 July; 2009.
    • (2009) Abstracts of the 25th Annual Meeting of ESHRE
    • Edeen Amr, S.1    Alhelou, Y.M.2
  • 27
    • 77955603273 scopus 로고    scopus 로고
    • Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis
    • M.A. Youssef, M. van Wely, and M.A. Hassan Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis Human Reproduction Update 16 2010 459 466
    • (2010) Human Reproduction Update , vol.16 , pp. 459-466
    • Youssef, M.A.1    Van Wely, M.2    Hassan, M.A.3
  • 30
    • 67849106650 scopus 로고    scopus 로고
    • Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas
    • S. Vallette, K. Serri, and J. Rivera Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas Pituitary 12 2009 153 157
    • (2009) Pituitary , vol.12 , pp. 153-157
    • Vallette, S.1    Serri, K.2    Rivera, J.3
  • 31
    • 79551501957 scopus 로고    scopus 로고
    • Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly
    • C. Izgi, H. Feray, C. Cevik, Y. Saltan, D. Mansuroglu, and K. Nugent Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly Journal of Heart Valve Disease 19 2010 797 800
    • (2010) Journal of Heart Valve Disease , vol.19 , pp. 797-800
    • Izgi, C.1    Feray, H.2    Cevik, C.3    Saltan, Y.4    Mansuroglu, D.5    Nugent, K.6
  • 32
    • 77955719568 scopus 로고    scopus 로고
    • Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia
    • T. Tan, I.Z. Cabrita, and D. Hensman Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia Clinical Endocrinology 73 2010 369 374
    • (2010) Clinical Endocrinology , vol.73 , pp. 369-374
    • Tan, T.1    Cabrita, I.Z.2    Hensman, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.